RLAY compared with AMLX: revenue, margins and what each company keeps, and the suppliers and customers both name

RLAYRelay Therapeutics, Inc.

Mkt capRevenueRevenue

AMLXAmylyx Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

RLAYRelay Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only RLAY 3

—D.E. Shaw Researchunlistedsupplier

—Elevar Therapeuticsunlistedcustomer

—Genentechunlistedcustomer

Shared 0

No disclosed counterparties: AMLX.

Only AMLX 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

RLAYRelay Therapeutics, Inc.

17.28▼−5.85%· post 17.28· delayed

Mkt cap$4.0BRevenue$350,000Q2 FY26

AMLXAmylyx Pharmaceuticals, Inc.

28.03▼−2.86%· post 28.04· delayed

After hoursNov 2 '26delayed

Mkt cap$3.2BRevenue$416,000Q3 FY24

Compare

After hoursNov 2 '26delayed

RLAYRelay Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals, Inc.

17.28▼−5.85%post 17.28delayed

Price

28.03▼−2.86%post 28.04delayed

$4.0B

Mkt cap

$3.2B

Q2 FY26$350,000

Revenue

$416,000Q3 FY24

RLAY17.28▼−5.85%vsAMLX28.03▼−2.86%After hoursNov 2 '26delayed